Theravance Biopharma, Inc.
TBPHDelisted Sep 23, 2026- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001583107
Theravance Biopharma, Inc. was delisted on Sep 23, 2026; its insiders filed their last Form 4 on Sep 28, 2026; 179 institutions reported holding it in 13F filings for Q2 2026, worth $817.5M in total; no superinvestor held it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 1
- Last 90 days, $226.8K in total
- 13F holders
- 179
- Q2 2026, +9 vs. previous quarter
- 13F value
- $817.5M
- Reported value at the end of Q2 2026
- Superinvestors holding
- 0
- At the end of Q2 2026
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $107.5M
- +66.9% year over year
- Net income, FY2025
- $105.9M
- No comparable prior period
- Free cash flow, FY2025
- $238.5M
- No comparable prior period
- Revenue, Q2 FY2026
- $20.7M
- −20.9% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net income for FY2025: $105.9M (98.5% of revenue).
Short interest
See short dataFrom FINRA, settlement date Sep 15, 2026.
- Short interest
- 1.69M
- Shares sold short
- Change
- +68.2K
- +4.2% vs. previous
- Days to cover
- 4.50
- At average daily volume
Superinvestors holding TBPH, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding TBPH at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Theravance Biopharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 (view filing)5:52 PM ET | Sep 15 | 2 days | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | SSale | −13.3K | $17.03 | −$226.8K | −5.9%213.5K after | 3 lots10b5-1 |
| Jul 8, 2026 (view filing)4:13 PM ET | Jul 6-7 | 2 days | Samaha Eli10% Owner | SSaleCOM | −6.96K | $17.14 | −$119.4K | −0.1%9.17M after | 2 lots |
| Jul 1, 2026 (view filing)7:33 PM ET | Jun 29-Jul 1 | 2 days | Samaha Eli10% Owner | SSaleCOM | −336.7K | $17.20 | −$5.79M | −3.5%9.17M after | 3 lots |
| Jun 17, 2026 (view filing) | Jun 15 | 2 days | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | SSale | −13.3K | $16.39 | −$218.2K | −5.4%232.5K after | 3 lots10b5-1 |
| Mar 18, 2026 (view filing) | Mar 16 | 2 days | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | SSale | −31.1K | $13.96 | −$433.7K | −11.8%232.7K after | 3 lots10b5-1 |
| Dec 5, 2025 (view filing) | Dec 3 | 2 days | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | SSale | −31.1K | $18.75 | −$582.5K | −10.1%277.7K after | 3 lots10b5-1 |
| Dec 1, 2025 (view filing) | Nov 26 | 5 days | Broshy EranDirector | SSale | −29.5K | $20.00 | −$590.0K | −39.8%44.7K after | 2 lots10b5-1 |
| Nov 14, 2025 (view filing) | Nov 11 | 3 days | Broshy EranDirector | SSale | −45.0K | $17.98 | −$809.3K | −42.8%60.2K after | Amended3 lots |
| Jul 16, 2025 (view filing) | Jul 14 | 2 days | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | SSale | −10.0K | $11.39 | −$113.9K | −3.0%326.9K after | 3 lots10b5-1 |
| Jun 4, 2025 (view filing) | Jun 2 | 2 days | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | SSale | −24.0K | $11.00 | −$264.0K | −6.6%336.9K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 179 holdersThe largest institutional positions in Theravance Biopharma, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Madison Avenue Partners, LP | 9,212,252 | $156.6M | 6.74% | −298,898−3.1% | Reduced |
| Weiss Asset Management LP | 7,457,060 | $126.8M | 1.42% | 00.0% | Unchanged |
| BlackRock, Inc. | 4,562,487 | $77.6M | 0.00% | +266,197+6.2% | Added |
| Newtyn Management, LLC | 3,434,191 | $58.4M | 7.29% | −1,407,438−29.1% | Reduced |
| Irenic Capital Management LP | 2,760,948 | $46.9M | 3.38% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 1,771,493 | $30.1M | 0.00% | −12,260−0.7% | Reduced |
| State Street Corp | 1,328,584 | $22.6M | 0.00% | +31,261+2.4% | Added |
| Two Sigma Investments, LP | 1,225,587 | $20.8M | 0.02% | −32,910−2.6% | Reduced |
| D. E. Shaw & Co., Inc. | 1,185,390 | $20.2M | 0.01% | +231,348+24.2% | Added |
| Acadian Asset Management LLC | 1,174,910 | $20.0M | 0.02% | −101,666−8.0% | Reduced |
Holders of 5% or more of TBPH
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Theravance Biopharma, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Madison Avenue Partners, LP | 13G/A | 17.70%9.21M shares | – | Sep 27, 20216 filings | Aug 14, 2026 | SEC |
| Newtyn Management, LLC | 13G/A | 6.70%3.43M shares | −1.80 ppfrom 8.50% | Aug 16, 20244 filings | Aug 14, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.50%3.24M shares | – | Oct 24, 20242 filings | Apr 30, 2025 | SEC |
Politician trades
All politician trades in TBPH1 member of Congress reported 1 trade in Theravance Biopharma, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Apr 23, 2025 |  George Whitesides House · CA | Sell | $15K-$50K |
House · CA · Apr 23, 2025
Sell$15K-$50K